Statins: Are Lipid-lowering Drugs Useful in Sarcomas?

Bone Tumours - A Comprehensive Review of Selected Topics(2023)

引用 0|浏览4
暂无评分
摘要
Sarcomas are rare tumors that are difficult to treat. Many of them are chemo-resistant and with a high tendency to recur. Hence, finding new treatments is imperative in these tumors. Metabolic changes in tumor biology have become an essential characteristic in carcinogenesis processes, highlighting among them the role of lipids in these events, mainly cholesterol biosynthesis. Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoAR), a key enzyme in the mevalonate pathway responsible for cholesterol synthesis, have an effect beyond the reduction in plasma cholesterol levels. These are the so-called pleiotropic effects of statins, responsible for some of the antitumor action of statins. Although there are considerable epidemiological and preclinical evidences that support the use of these medicaments in the treatment of sarcomas as adjuvant reprofiled drugs, clinical trials are disparate and heterogeneous, and do not provide enough information to help determine the convenience of their use, being necessary more studies to evaluate the efficacy and safety of statins in sarcomas. The purpose of this review is to update the role played by the reprofiled statins in the treatment of sarcomas.
更多
查看译文
关键词
statins,sarcomas,lipid-lowering
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要